CN101987844B - Method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride - Google Patents

Method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride Download PDF

Info

Publication number
CN101987844B
CN101987844B CN 200910144407 CN200910144407A CN101987844B CN 101987844 B CN101987844 B CN 101987844B CN 200910144407 CN200910144407 CN 200910144407 CN 200910144407 A CN200910144407 A CN 200910144407A CN 101987844 B CN101987844 B CN 101987844B
Authority
CN
China
Prior art keywords
chlorobenzyl
methyl
hydrochloride
phthalizine
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN 200910144407
Other languages
Chinese (zh)
Other versions
CN101987844A (en
Inventor
于振云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EASTSKY PHARM (ANHUI) TECHNOLOGY Co.,Ltd.
GUANGDONG XIANQIANG PHARMACEUTICAL Co.,Ltd.
Original Assignee
TONGLING KAISHUN BIOLOGY TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TONGLING KAISHUN BIOLOGY TECHNOLOGY Co Ltd filed Critical TONGLING KAISHUN BIOLOGY TECHNOLOGY Co Ltd
Priority to CN 200910144407 priority Critical patent/CN101987844B/en
Publication of CN101987844A publication Critical patent/CN101987844A/en
Application granted granted Critical
Publication of CN101987844B publication Critical patent/CN101987844B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention relates to a method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride (azelastine). The method is characterized in that: common chemical raw materials comprising N-methyl hexahydrodiazepoxide-4-ketone hydrochloride and 4-(4-chlorobenzyl)-1-(2H)-phthalizine ketone are used as raw materials; the 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride (azelastine) is synthesized in one step by condensation reaction; the total yield is 67 percent and exceeds the yield reported by the conventional documents; and the production cost is reduced. The method avoids the combustible and explosive synthesis steps of ring expansion and hydrazide treatment in the conventional synthesis processes, and does not cause personal injury of operators. The method has mild reaction conditions, and is easy to control and realize industrialization.

Description

The synthetic method of a kind of 4-(4-chlorobenzyl)-2-(six hydrogen-1-methyl isophthalic acid H-nitrogen Zhuo-4-yl)-1-(2H)-phthalazinium hydrochlorate
Affiliated technical field
The present invention relates to the synthetic method of a kind of 4-(4-chlorobenzyl)-2-(six hydrogen-1-methyl isophthalic acid H-nitrogen Zhuo-4-yl)-1-(2H)-phthalazinium hydrochlorate (W-2979M), belong to the fine chemistry industry production field.
Background technology
4-(4-chlorobenzyl)-2-(six hydrogen-1-methyl isophthalic acid H-nitrogen Zhuo-4-yl)-1-(2H)-phthalazinium hydrochlorate (W-2979M) is developed by German Asta-Werke AG company and Japanese Wei Cai company, and is in widespread attention since the listing.This product all has production in states such as U.S., moral, English, day and methods at present, and takes in British Pharmacopoeia.Estimate that the listing of anti-asthma new drug W-2979M will change the structure of present treatment of allergic rhinitis and asthma medication greatly, this product is widely used in treatment of allergic rhinitis and skin pruritus and asthma clinically, in addition, recent years abroad has also been obtained good curative effect with its treatment allergic skin itch, eczema and various dermatitis, has huge market capacity, wide market outlook and the powerful market competitiveness.
2003 34 (1) reports of Chinese Journal of Pharmaceuticals are take N-methyl piperidine-4-ketone as raw material. synthesized the allergy preparations W-2979M through reactions such as ring expansion, hydrazides, condensations. and overall yield of reaction 48.6%, equation is as follows:
Figure G2009101444070D00021
Summary of the invention
The object of the invention is to adopt that raw material is easy to get, synthetic route is short, avoided ring expansion, these inflammable and explosive synthesis steps of hydrazidesization.Provide a kind of and can not cause personal injury to operator, synthetic route is short, reaction conditions is gentle, safety easily the row, yield is high, cost is low, be easy to realize industrialized synthetic method.
The present invention realizes above-mentioned purpose by following technical solution:
Adopting in the present invention N-methyl six hydrogen azatropylidene-4-keto hydrochloride and 4-(4-chlorobenzyl)-1-(2H)-phthalazone is raw material, through condensation reaction one-step synthesis 4-(4-chlorobenzyl)-2-(six hydrogen-1-methyl isophthalic acid H-nitrogen Zhuo-4-yl)-1-(2H)-phthalazinium hydrochlorate (W-2979M), its chemical equation is as follows:
Figure G2009101444070D00022
The present invention compared with prior art has following beneficial effect: the present invention is take N-methyl six hydrogen azatropylidene-4-keto hydrochloride as raw material, and through condensation reaction one-step synthesis W-2979M, total recovery reaches yield 67%, surpasses the yield of existing bibliographical information; Avoid adopting in the conventional building-up process ring expansion, these inflammable and explosive synthesis steps of hydrazidesization, can not cause personal injury to operator.
Description of drawings
Fig. 1 is the chemical structural formula of W-2979M;
Fig. 2 is the reacting flow chart of synthetic hydrochloric acid azelastine.
Embodiment
The present invention can realize by following concrete steps:
Getting 350g N-methyl six hydrogen azatropylidene-4-keto hydrochloride puts in 10~12 times of dehydrated alcohols and dissolves, be cooled to 5 ℃, add the 100g POTASSIUM BOROHYDRIDE, add the fashionable Bubble formation that has, to slowly add, be warming up to 20-25 ℃ after adding, keep adding after 12 hours 4-(4-chlorobenzyl)-1-(2H)-phthalazone, then solution temperature rising reflux 3 hours is cooled to 0~5 ℃ and stirred 2 hours, filters out solid, filtrate decompression is distilled to dried, the dope of gained is dissolved in the acetone, adds activated carbon decolorizing, filter.Filtrate is regulated PH=1--2 with hydrochloric acid, remains on 0-5 ℃ of lower the stirring 5 hours, filters washing with acetone, absolute ethanol washing, dry white powder solid, the W-2979M 600g of getting.Yield 67%.Content 99%, fusing point 222-225 ℃.

Claims (1)

1. the synthetic method of an azelastine Hcl, it is characterized in that: get 350g N-methyl six hydrogen azepine-4-keto hydrochloride and put in 10~12 times of dehydrated alcohols and dissolve, be cooled to 5 ℃, add the 100g POTASSIUM BOROHYDRIDE, add the fashionable Bubble formation that has, to slowly add, be warming up to 20-25 ℃ after adding, keep adding after 12 hours 4-(4-chlorobenzyl)-1-(2H)-phthalazone, solution temperature rising reflux 3 hours, then being cooled to 0~5 ℃ stirred 2 hours, filter out solid, filtrate decompression is distilled to dried, and the dope of gained is dissolved in the acetone, add activated carbon decolorizing, filter; Filtrate is regulated pH=1-2 with hydrochloric acid, remains on 0-5 ℃ of lower the stirring 5 hours, filters washing with acetone, absolute ethanol washing, dry white powder solid, azelastine Hcl 600g, yield 67%, content 99%, fusing point 222-225 ℃ of getting.
CN 200910144407 2009-08-04 2009-08-04 Method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride Active CN101987844B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200910144407 CN101987844B (en) 2009-08-04 2009-08-04 Method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200910144407 CN101987844B (en) 2009-08-04 2009-08-04 Method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride

Publications (2)

Publication Number Publication Date
CN101987844A CN101987844A (en) 2011-03-23
CN101987844B true CN101987844B (en) 2013-04-03

Family

ID=43744658

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200910144407 Active CN101987844B (en) 2009-08-04 2009-08-04 Method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride

Country Status (1)

Country Link
CN (1) CN101987844B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102391253A (en) * 2011-10-24 2012-03-28 贵州云峰药业有限公司 Synthetic technology of azelastine hydrochloride
CN102702108A (en) * 2012-06-27 2012-10-03 上海大学 1,2-dihydrophthalazin compound and synthetic method thereof
CN102863393A (en) * 2012-09-26 2013-01-09 上海大学 1,2-dihydro phthalazine compound and synthetic method thereof
CN104173352B (en) * 2014-09-10 2016-06-01 贵州云峰药业有限公司 W-2979M pharmaceutical composition
CN113045547B (en) * 2019-12-27 2023-03-28 武汉先路医药科技股份有限公司 Preparation method of azelastine hydrochloride

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0488209A1 (en) * 1990-11-28 1992-06-03 Eisai Chemical Co., Ltd. Process for producing benzylphthalazinone derivatives and salts thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05230056A (en) * 1992-02-19 1993-09-07 Sumika Fine Kemu Kk Production of 4-substituted benzyl-2-(n-substituted hexahydroazepinyl)-1(2h)-phthalazinone derivative

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0488209A1 (en) * 1990-11-28 1992-06-03 Eisai Chemical Co., Ltd. Process for producing benzylphthalazinone derivatives and salts thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JP特开平5-230056A 1993.09.07

Also Published As

Publication number Publication date
CN101987844A (en) 2011-03-23

Similar Documents

Publication Publication Date Title
CN101987844B (en) Method for synthesizing 4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-diazepoxide-4-radical)-1-(2H)-phthalizine hydrochloride
CN105820110B (en) Mo Fanselin synthetic methods
CN103724261B (en) A kind of industrialized process for preparing of hydroxychloroquine sulfate quinoline
CN102295638B (en) Novel method for preparing lapatinib
CN109912508A (en) A kind of preparation method of Dexmedetomidine and its hydrochloride
CN102746288B (en) Preparation methods of anticoagulant and key intermediate of anticoagulant
CN106674084B (en) A kind of preparation method of 2- isopropyl oxygroup -5- methyl -4- (piperidin-4-yl) aniline dihydrochloride
CN100376559C (en) Method for preparing secnidazole
CN104961692A (en) Improved preparation method of 7-chlorin-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepine-2-keto-4-oxide
CN104926599A (en) Method for preparing high-purity 4,4'-bis(chloromethyl)-1,1'-biphenyl under novel solvent system
CN106187887B (en) The preparation method of 4- oxyquinoline -3- formic acid
CN101575301B (en) Preparation method of 2-amino-5-chlorobenzamide
CN105884746B (en) The synthetic method of fluorine imatinib
CN101168532B (en) Method for synthesizing N-methylpiperazine substituted anilin
CN107827812B (en) Chiral synthesis method of bepotastine besilate intermediate
CN106699730A (en) Preparation method of 2-methyl-5-(5-bromopyridine-2-group) tetrazole
CN102603521A (en) Preparation method of 2,3,4,5-tetrafluorobenzoyl chloride
CN107200691A (en) Replace the preparation method of class para-phenylene diamine dihydrochloride
CN103992241B (en) The preparation method of N-substituted-phenyl glycine
CN112538074A (en) Preparation method of debrominated impurities of brimonidine
CN105439969A (en) Method for preparing 3,5-dioxo-1,2,4-triazole
CN102391170B (en) A kind of preparation method of N, N-diallyl-5-methoxytryptamine hydrochlorides
CN107915694A (en) 1 [2 (2,4 3,5-dimethylphenyl sulfydryl) phenyl] piperazine hydrochloride and preparation method thereof
CN104230717B (en) One prepares the method for 2,2 '-two (trifluoromethyl)-4,4 '-dinitro diphenyl ether
CN113387893B (en) Synthetic method of oxamil

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ANHUI EASTSKY BIOTECHNOLOGY CO., LTD.

Free format text: FORMER OWNER: TONGLING KAISHUN BIOLOGY TECHNOLOGY CO., LTD.

Effective date: 20150603

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 244000 TONGLING, ANHUI PROVINCE TO: 235200 SUZHOU, ANHUI PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20150603

Address after: 235200 Xiaoxian, Anhui, Suzhou Village Industrial Park

Patentee after: EASTSKY PHARM (ANHUI) TECHNOLOGY CO., LTD.

Address before: 244000 B315, HKUST, Tongling economic and Technological Development Zone, Anhui

Patentee before: Tongling Kaishun Biology Technology Co., Ltd.

TR01 Transfer of patent right

Effective date of registration: 20200703

Address after: 235200, Ji Cun Industrial Park, Suzhou, Anhui, Xiaoxian

Co-patentee after: GUANGDONG XIANQIANG PHARMACEUTICAL Co.,Ltd.

Patentee after: EASTSKY PHARM (ANHUI) TECHNOLOGY Co.,Ltd.

Address before: 235200, Ji Cun Industrial Park, Suzhou, Anhui, Xiaoxian

Patentee before: EASTSKY PHARM (ANHUI) TECHNOLOGY Co.,Ltd.

TR01 Transfer of patent right